StockData

Kiniksa Pharmaceuticals International vs Madrigal Pharmaceuticals

KNSA and MDGL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KNSA and MDGL compare

Kiniksa Pharmaceuticals International is the larger company, worth 1.5 times as much as Madrigal Pharmaceuticals ($14.8B against $9.8B).

Madrigal Pharmaceuticals grew revenue faster over the last twelve months (149% versus 58.2% for Kiniksa Pharmaceuticals International).

Kiniksa Pharmaceuticals International keeps more of each dollar of sales as profit, with a net margin of 11.6% compared with −25.3% at Madrigal Pharmaceuticals.

Kiniksa Pharmaceuticals International scores higher on the StockData Score (14 against 5 for Madrigal Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKNSAMDGL
Size and price
Market cap$14.8B$9.8B
Share price$94.23$423.96
Change, 1 year134%−17.7%
Change, 5 years709%417%
Beta (5Y)0.170.39
Employees366915
StockData Score
Total score14 (better)5
Valuation score00
Growth score4 (better)1
Performance score4 (better)2
Health score6 (better)2
Dividend score00
Valuation
P/E72.5×–
P/S15.7×7.6× (better)
P/B20.9×18.7× (better)
EV/EBITDA108×–
P/FCF75.1×–
FCF yield1.3% (better)−2.1%
Fair value$16.81$408.88
Margin of safety−461%−3.7% (better)
Growth
Revenue growth (TTM)58.2%149% (better)
Net income growth (TTM)205%–
EPS growth (TTM)189%–
Profitability
Gross margin90.2%–
Operating margin13.8% (better)−25.1%
Net margin11.6% (better)−25.3%
FCF margin20.8% (better)−16.1%
Return on equity17.6% (better)−53.3%
Return on invested capital60.2% (better)−1338%
Financial health
Debt / equity0.000.65 (better)
Interest coverage–−10.2×
Current ratio3.91 (better)3.20
Altman Z-score34.10 (better)6.60
Piotroski F-score8 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions29.9%103%
Held by insiders5.1%27.2%
Insider net buying, 12 months−$122M−$33.3M (better)
Superinvestors holding–1
Short interest, % of float2.9%12.7%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.